Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

Poster to be Presented at the 47th Annual Interscience Conference on

Antimicrobial Agents and Chemotherapy

LOUISVILLE, Colo., Sept. 19 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that in preclinical studies, its antibacterial candidate REP3123 is shown to inhibit growth and prevent spore-forming of the Gram-positive Clostridium difficile (C. difficile) bacterium without inhibiting other key organisms that are essential for normal intestinal functioning. C. difficile-associated disease (CDAD), a major cause of morbidity among the elderly and hospitalized patients, is acquired by ingesting spores present in the environment that then grow and multiply in the gut. In preclinical studies, REP3123 was superior to two agents widely used to treat C. difficile infections, vancomycin and metronidazole, in preventing the organism from forming spores. The study results suggest that REP3123 has the potential to reduce the presence of spores in the intestine, subsequently preventing dissemination into the environment, thereby potentially reducing outbreak and relapse rates.

These results will be presented on Thursday, September 20, 2007 at 10:00 AM in Room E253D by Ian A. Critchley, Ph.D., Executive Director, Microbiology at Replidyne during poster session 229 titled, "New Agents Active Against Clostridium difficile" at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy held at the McCormick Place conference center in Chicago.

REP3123 is a new narrow spectrum antibacterial agent that in vitro prevents the growth of C. difficile by inhibiting an essential enzyme in the bacterial cell called methionyl tRNA synthetase, which blocks the o
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... and a live Internet webcast along with a slide presentation ... a.m. PT) to discuss results for the 2010 fourth quarter ... on this call is (877) 295-5743, confirmation code 41335702.  International ...
... Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical company, announced the ... class of anti-cancer therapeutics based upon Smac mimetics.  Smac ... pathway and have broad potential for the treatment of ... The United States Patent and Trademark Office (USPTO) granted ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest hosting ranking ... are the best VPS hosting suppliers in the ... method of partitioning a physical server computer into ... and capabilities of running on someone’s own dedicated ... attention to VPS products and related suppliers. ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... NY (PRWEB) October 20, 2014 Stephen T. ... has been nominated for the 10th consecutive year as one ... year Dr. Greenberg was also been nominated as the best ... was also nominated as best Day Spa and best Laser ... until December 14th and readers can vote for the contest ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... informed about the risks and benefits of taking part ... as vigorously as new medical treatments themselves, a study ... , Informed consent, a mainstay of ethical clinical trials, ... asked to decide whether to participate in research. The ...
... Center say they have evidence that cancer stem cells ... cells and have multiple ways of resisting chemotherapy and ... in the Jan. 1 issue of the journal Cancer ... the Johns Hopkins scientists say, and pave the way ...
... ANGELES, Jan. 11 The Guidebook of ... "the couple" as the main unit for,treatment ... significant emphasis,on the thorough evaluation of biological ... medications) and psychosocial factors (e.g.,presence of depression, ...
... Just in Case, Inc., the makers of,the first ... of their compacts to women,s Non-Profit Groups Nationwide. They ... state will be,chosen to receive 100 JUST IN CASE(R) ... Day., The 10,000 compact give-away will help raise ...
... Conn., Jan. 9 dLifeTV, the first and only,television ... lineup for its eighth season premiering January 20th. Airing,Sundays ... season,s featured,celebrities living with diabetes include TV icon Jerry ... managed fame for over 40 years and his diabetes,for ...
... The World Bank and Conservation International (CI) today ... provided by the Global Environment Facility (GEF), to protect ... including island ecosystems and temperate forests. , These biodiversity ... terrestrial plants and animals, as well as more than ...
Cached Medicine News:Health News:Ways to improve informed consent are testable, study says 2Health News:Stem cells make bone marrow cancer resistant to treatment 2Health News:Stem cells make bone marrow cancer resistant to treatment 3Health News:A New Book on Sexual Medicine Calls Attention to 'The Couple' and Presents State-of-the Art Treatments for Sexual Dysfunction 2Health News:Teen Pregnancy Epidemic Another Reason for Women to Carry Condoms. Just in Case, Inc. Announces 10,000 Chic Condom Compact Give-Away to Women's Non-Profits Nationwide. 2Health News:dLIFETV Premieres Eighth Season With Baseball's 'Comeback Player' Dmitri Young and Leave It To Beaver's Jerry Mathers 2Health News:Global Environment partners provide additional $20 million to protect endangered habitats 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: